Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.44+0.03 (+2.13%)
Close on Nov 18, 2026Market cap $14.32MP/E –Yield –
Seres Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Seres Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$51.26M. For fiscal 2025 it was $1.12M. The highest annual figure on record is $43.92M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12M | – |
| FY2024 | Dec 31, 2024 | -$148.61M | – |
| FY2023 | Dec 31, 2023 | -$117.35M | – |
| FY2022 | Dec 31, 2022 | -$228.82M | -3521.3% |
| FY2021 | Dec 31, 2021 | $6.69M | – |
| FY2020 | Dec 31, 2020 | -$93.61M | – |
| FY2019 | Dec 31, 2019 | -$76.52M | – |
| FY2018 | Dec 31, 2018 | -$62.85M | – |
| FY2017 | Dec 31, 2017 | -$75.52M | -272.0% |
| FY2016 | Dec 31, 2016 | $43.92M | – |
| FY2015 | Dec 31, 2015 | -$40.84M | – |
| FY2014 | Dec 31, 2014 | -$10.36M | – |
| FY2013 | Dec 31, 2013 | -$5.32M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.36M | -160.8% |
| Q4 FY2025 | Dec 31, 2025 | -$14.71M | – |
| Q3 FY2025 | Sep 30, 2025 | $2.21M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.29M | – |
| Q1 FY2025 | Mar 31, 2025 | $26.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$38.88M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.68M | – |
| Q2 FY2024 | Jun 30, 2024 | -$39.81M | -160.3% |
| Q1 FY2024 | Mar 31, 2024 | -$35.24M | – |
| Q4 FY2023 | Dec 31, 2023 | -$47.50M | – |
| Q3 FY2023 | Sep 30, 2023 | -$59.26M | – |
| Q2 FY2023 | Jun 30, 2023 | $65.98M | – |
| Q1 FY2023 | Mar 31, 2023 | -$76.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$52.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$59.58M | -146.6% |
| Q2 FY2022 | Jun 30, 2022 | -$49.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$66.45M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.86M | – |
| Q3 FY2021 | Sep 30, 2021 | $127.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$39.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.50M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.93M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.57M | – |
| Q1 FY2020 | Mar 31, 2020 | -$24.25M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.05M | -210.9% |
| Q3 FY2019 | Sep 30, 2019 | -$18.29M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.79M | – |
| Q1 FY2019 | Mar 31, 2019 | -$32.39M | – |
| Q4 FY2018 | Dec 31, 2018 | $12.67M | – |
| Q3 FY2018 | Sep 30, 2018 | -$23.08M | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.67M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.76M | – |
| Q4 FY2017 | Dec 31, 2017 | -$20.61M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.61M | – |
| Q2 FY2017 | Jun 30, 2017 | -$25.66M | – |
| Q1 FY2017 | Mar 31, 2017 | -$25.65M | – |
| Q4 FY2016 | Dec 31, 2016 | -$20.81M | – |
| Q3 FY2016 | Sep 30, 2016 | -$11.37M | – |
See a number that looks wrong?